Tumor cells overexpressing the Arp2/3 complex subunits or activating the Arp2/3 complex through the RAC1 oncogene are sensitive to Arp2/3 inhibition (Liu et al., 2013; Molinie et al., 2019). This evidence concerns the gene ACTR2 and neoplasm.